ASKA Aims for 70 Billion Yen Sales by FY2025 on Growth of OB-GYN, Thyroid Spaces: New Biz Plan

March 23, 2021
ASKA Pharmaceutical aims to notch up consolidated sales of 70 billion yen, an operating profit rate of 8%, and a return on equity (ROE) of 8% under its new five-year business plan from FY2021, the company said on March 22...read more